Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Thursday.
A number of other research firms have also weighed in on ACRS. Cantor Fitzgerald set a $50.00 price target on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a research report on Friday, December 15th. Zacks Investment Research lowered shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Three investment analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $39.20.
Shares of Aclaris Therapeutics (ACRS) opened at $24.40 on Thursday. Aclaris Therapeutics has a 52-week low of $21.32 and a 52-week high of $33.25. The stock has a market cap of $740.61 and a PE ratio of -11.30.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Citigroup Inc. boosted its position in Aclaris Therapeutics by 171.8% during the second quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 2,726 shares during the last quarter. Legal & General Group Plc boosted its position in Aclaris Therapeutics by 98.3% during the second quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock worth $142,000 after acquiring an additional 2,605 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Aclaris Therapeutics during the third quarter worth about $142,000. Voya Investment Management LLC acquired a new position in Aclaris Therapeutics during the second quarter worth about $247,000. Finally, PNC Financial Services Group Inc. boosted its position in Aclaris Therapeutics by 26.0% during the second quarter. PNC Financial Services Group Inc. now owns 9,220 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 1,900 shares during the last quarter. Hedge funds and other institutional investors own 92.02% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Aclaris Therapeutics (ACRS) Stock Rating Lowered by BidaskClub” was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://weekherald.com/2018/01/20/aclaris-therapeutics-acrs-stock-rating-lowered-by-bidaskclub.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.